Urology Vol. II
Three topics, 32 cases — choose one below to browse its cases.
First-line overactive bladder therapy and the anticholinergic-dementia signal, vaginal estrogen for recurrent UTI prevention in a breast-cancer survivor on an aromatase inhibitor, methenamine versus stone-prevention chemistry, duloxetine for stress incontinence, botulinum toxin versus sacral neuromodulation, sex-specific desmopressin dosing, off-label alpha-blockade after a sling, and preoperative vaginal estrogen before prolapse surgery
Escalating oral therapy versus injection for neurogenic detrusor overactivity, onabotulinumtoxinA dosing at the labeled ceiling, autonomic dysreflexia prophylaxis with a PDE5-inhibitor/nitrate interaction, off-label alpha-blockade for detrusor-sphincter dyssynergia, asymptomatic bacteriuria versus true infection, anticholinergic burden and dementia risk, dopaminergic versus bladder-directed therapy in Parkinson disease, and desmopressin for nocturnal polyuria in multiple sclerosis
Exogenous testosterone alternatives with active fertility plans, post-cycle hypogonadism after anabolic steroid use, PDE5 inhibitor dosing strategy, penile rehabilitation after prostatectomy, injection therapy escalation, ischemic priapism management, Peyronie's disease treatment, premature ejaculation pharmacotherapy, testosterone therapy after prostate cancer, and erythrocytosis on testosterone therapy